Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


2nd Novel Cancer Therapeutics Summit

25 Feb 2013 - 26 Feb 2013 - Las Vegas, NV, USA



Bookmark and Share


We welcome you to GTC's 2nd Novel Cancer Therapeutics Summit taking place on February 25-26, 2013 in Las Vegas, NV.  This summit brings together experts from academia and industry to discuss the emerging targets, therapeutics and strategies against cancer, as well as showcase ubiquitins' huge potential in the development of therapeutics.  Attendees will also receive updates on government policy, recent regulations, important investments and partnering strategies.


2nd Novel Cancer Therapeutics Summit
 consists of three concurrent conferences shown below:

 - 4th Cancer Targets & Therapeutics
 - 2nd Oncology Partnering & Deal-making
 - 3rd Ubiquitin Research & Drug Discovery  


Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. The 2nd Novel Cancer Therapeutics Summit will provide a great opportunity for companies to expose products and services


Call for Papers!
To be considered for an oral presentation, please submit an abstract here by January 25, 2013. Selected presentations will be based on quality of abstract and availability. Presentation slots fill up fast so please submit your abstract ASAP.



Further information
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!